Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture.
Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

Pharmaceuticals

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

GADODIAMIDE CRS (300 MG)

GADODIAMIDE CRS (300 MG)

131410-48-5

DISCOVER
GADODIAMIDE IMPURITY A CRS (15 MG)

GADODIAMIDE IMPURITY A CRS (15 MG)

NA

DISCOVER
GADODIAMIDE IMPURITY B CRS (15 MG)

GADODIAMIDE IMPURITY B CRS (15 MG)

NA

DISCOVER
MINOCYCLINE FOR SYSTEM SUITABILITY CRS (10 MG)

MINOCYCLINE FOR SYSTEM SUITABILITY CRS (10 MG)

13614-98-7

DISCOVER
(25R)-SPIROST-5-EN-3-ONE CRS (10 MG)

(25R)-SPIROST-5-EN-3-ONE CRS (10 MG)

20817-62-3

DISCOVER
MILBEMYCIN OXIME FOR SYSTEM SUITABILITY CRS (10 MG)

MILBEMYCIN OXIME FOR SYSTEM SUITABILITY CRS (10 MG)

129496-10-2

DISCOVER
ALFUZOSIN FOR PEAK IDENTIFICATION CRS (10 MG)

ALFUZOSIN FOR PEAK IDENTIFICATION CRS (10 MG)

81403-68-1

DISCOVER
REMIFENTANIL IMPURITY MIXTURECRS - * NARC (REMIFENTANIL HYD

REMIFENTANIL IMPURITY MIXTURECRS - * NARC (REMIFENTANIL HYD

132539-07-2

DISCOVER
PROGUANIL FOR SYSTEM SUITABILITY CRS (15 MG)

PROGUANIL FOR SYSTEM SUITABILITY CRS (15 MG)

637-32-1

DISCOVER
E2 COLISTIMETHATE SODIUM FOR PEAK IDENTIFICATION CRS (5 MG)

E2 COLISTIMETHATE SODIUM FOR PEAK IDENTIFICATION CRS (5 MG)

8068-28-8

DISCOVER
E1 COLISTIMETHATE SODIUM FOR PEAK IDENTIFICATION CRS (5 MG)

E1 COLISTIMETHATE SODIUM FOR PEAK IDENTIFICATION CRS (5 MG)

8068-28-8

DISCOVER
COLISTIMETHATE SODIUM FOR PEAK IDENTIFICATION CRS (20 MG)

COLISTIMETHATE SODIUM FOR PEAK IDENTIFICATION CRS (20 MG)

8068-28-8

DISCOVER